v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (884,000) $ (601,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 286,000 322,000
Equity compensation expense 51,000 17,000
Change in assets and liabilities:    
Accounts receivable 2,660,000 1,608,000
Inventories 911,000 313,000
Prepaid expenses and other assets (68,000) 169,000
Trade payables (195,000) (104,000)
Operating leases 22,000 40,000
Advance investor deposit 75,000
Accrued liabilities (323,000) (50,000)
Net cash (used in) provided by operating activities 2,535,000 1,714,000
Cash flows from investing activities:    
Purchases of property, plant and equipment (30,000) (42,000)
Net cash (used in) provided by investing activities (30,000) (42,000)
Cash flows from financing activities:    
Repayment of note payable (51,000) (42,000)
Net repayments on revolving line of credit (2,231,000) (1,832,000)
Net cash provided by (used in) financing activities (2,282,000) (1,874,000)
Net increase (decrease) in cash and cash equivalents 223,000 (202,000)
Cash and cash equivalents at beginning of period 97,000 220,000
Cash and cash equivalents at end of period 320,000 18,000
Supplemental disclosure of cash flow information and noncash investing and financing activities:    
Cash payments for interest 467,000 465,000
Accretion of dividends on preferred stock 86,000 86,000
Conversion of advance received from investors into common stock 1,050,000
Common stock issued in exchange for rent due to Icy Mellon $ 182,000